Preventing Bladder Cancer Recurrence: The BART Trial

Reducing the risk of bladder cancer recurrence remains a significant challenge in oncological care. In patients with high-risk muscle-invasive bladder cancer (MIBC), radical cystectomy combined with perioperative chemotherapy is the standard of care. However, pelvic recurrences still occur frequently. Consequently, researchers from the Tata Memorial Centre in Mumbai led the phase-3 Bladder Adjuvant Radiotherapy (BART) randomized controlled trial. Specifically, this study examined whether adjuvant pelvic radiation therapy improves clinical outcomes in high-risk MIBC patients.

Efficacy and Survival Outcomes

The clinical trial enrolled 153 patients with nonmetastatic muscle-invasive bladder cancer across four academic centers in India. Specifically, seventy-one percent of these participants received neoadjuvant chemotherapy, while twenty percent received adjuvant chemotherapy. Researchers then randomized the patients to either adjuvant intensity-modulated radiation therapy (IMRT) or simple observation. Notably, the radiotherapy group achieved a two-year locoregional recurrence-free survival of 87.1 percent. In contrast, the observation group achieved only 76 percent. Thus, pelvic radiotherapy significantly improved local disease control. Furthermore, the radiotherapy group showed superior numbers for overall survival and disease-free survival. These survival secondary endpoints, however, did not reach statistical significance.

Toxicity and Clinical Implementation

Safety is a crucial consideration when introducing adjuvant pelvic radiotherapy. Fortunately, intensity-modulated radiation therapy (IMRT) delivered pelvic radiation safely without adding severe toxicities. In fact, severe late-stage adverse events occurred at similar rates between the two groups. Therefore, these results strongly support integrating adjuvant pelvic IMRT into routine care for high-risk patients. Nevertheless, the researchers noted some limitations in the trial. For instance, fourteen patients randomized to radiotherapy did not receive the treatment. Additionally, none of the trial patients received immunotherapy. Consequently, clinicians must consider these factors when applying these findings to modern medical practices.

Frequently Asked Questions

Q1: What is the main finding of the BART trial regarding bladder cancer recurrence?

The BART trial demonstrated that adjuvant pelvic radiation therapy significantly reduces the risk of locoregional bladder cancer recurrence in high-risk patients. Specifically, the two-year locoregional recurrence-free survival was 87.1 percent in the radiotherapy group compared to 76 percent in the observation group.

Q2: Does post-surgery radiotherapy improve overall survival in muscle-invasive bladder cancer?

While the radiotherapy group showed higher numerical rates of overall survival and disease-free survival, these differences were not statistically significant. However, the treatment significantly improved locoregional disease control with minimal added severe toxicities.

Q3: What are the key limitations of the BART study?

First, fourteen patients in the trial did not receive their planned radiotherapy. Second, the trial did not incorporate immunotherapy, which is a major component of modern bladder cancer treatment protocols.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.

References

1. Post-surgery radiation therapy lowers risk of bladder cancer recurrence, studysuggests - ETHealthworld
2. Murthy V, Maitre P, Pal M, et al. Bladder Adjuvant Radiotherapy: Phase III Multicenter Randomized Controlled Trial of Adjuvant Radiotherapy or Observation for Postcystectomy Muscle-Invasive Bladder Cancer. Journal of Clinical Oncology. 2026.